Pan Yan, Zhao Lei, Chen Xing-Miao, Gu Yong, Shen Jian-Gang, Liu Lu-Ming
Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China E-mail :
Asian Pac J Cancer Prev. 2013;14(10):5761-7. doi: 10.7314/apjcp.2013.14.10.5761.
The potential correlation of X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln polymorphism with hepatocellular carcinoma (HCC) susceptibility is ambiguous. Taking account of inconsistent results of previous meta-analyses and new emerging literatures, we conducted a meta-analysis covering 15 case-control datasets to evaluate the relationship. Relevant studies from Medline, Embase and CNKI were retrieved. A fixed- effect model or a random-effect model, depending on between-study heterogeneity, were applied to estimate the association between XRCC1 polymorphism Arg399Gln and HCC risk with the results presented as odds ratios (ORs) and 95% confidence intervals (95% CIs). In accordance with Hardy-Weinberg equilibrium, 15 studies with data for 6,556 individuals were enrolled in this systematic review. For overall HCC,thr XRCC1 polymorphism Arg399Gln was significantly associated with HCC susceptibility in a homozygote model as well as in a dominant model (G/G vs. A/A, OR=1.253, p=0.028; G/G+A/G vs. A/A, OR= 1.281, p=0.047, respectively), but not in a heterozygote model (A/G vs. A/A, OR=1.271, p=0.066) or a recessive model (G/G vs. A/G + A/A, OR= 1.049, p=0.542). Similar results were also observed on stratification analysis by ethnicity (A/G vs. A/A, OR=1.357, p=0.025; G/G vs. A/A, OR=1.310, p=0.011; G/G+A/G vs. A/A, OR= 1.371, p=0.013). However, no potential contribution of XRCC1 Arg399Gln polymorphism to HCC susceptibility in HBV/HCV subgroups was identified. No publication bias was found in this study. In conclusion, the XRCC1 Arg399Gln polymorphism contributes to HCC susceptibility. Due to the lack of studies in Western countries, further large-sample and rigorous studies are needed to validate the findings.
X射线修复交叉互补基因1（XRCC1）的精氨酸399谷氨酰胺多态性与肝细胞癌（HCC）易感性之间的潜在相关性尚不明确。鉴于以往荟萃分析结果不一致以及新出现的文献，我们进行了一项涵盖15个病例对照数据集的荟萃分析，以评估二者之间的关系。检索了来自Medline、Embase和中国知网的相关研究。根据研究间的异质性，采用固定效应模型或随机效应模型来估计XRCC1多态性精氨酸399谷氨酰胺与HCC风险之间的关联，结果以比值比（OR）和95%置信区间（95%CI）表示。根据哈迪-温伯格平衡，本系统评价纳入了15项涉及6556名个体数据的研究。对于总体HCC，XRCC1多态性精氨酸399谷氨酰胺在纯合子模型以及显性模型中均与HCC易感性显著相关（G/G与A/A相比，OR = 1.253，p = 0.028；G/G + A/G与A/A相比，OR = 1.281，p = 0.047），但在杂合子模型（A/G与A/A相比，OR = 1.271，p = 0.066）或隐性模型（G/G与A/G + A/A相比，OR = 1.049，p = 0.542）中并非如此。在按种族进行分层分析时也观察到了类似结果（A/G与A/A相比，OR = 1.357，p = 0.025；G/G与A/A相比，OR = 1.310，p = 0.011；G/G + A/G与A/A相比，OR = 1.371，p = 0.013）。然而，未发现XRCC1精氨酸399谷氨酰胺多态性对HBV/HCV亚组中HCC易感性有潜在影响。本研究未发现发表偏倚。总之，XRCC1精氨酸399谷氨酰胺多态性与HCC易感性有关。由于西方国家缺乏相关研究，需要进一步开展大样本且严谨的研究来验证这些发现。
